April 18, 2019 10:11 AM EDTUpdated 10:39 AM

Genfit wins BTD status at FDA for its lead drug for liver disease; Idorsia outlines $530M '19 spending plans on late-stage R&D

John Carroll

Editor & Founder

→ Genfit $GNFT is getting a helping hand from the FDA with its lead drug elafibranor, in development for primary biliary cholangitis, a liver disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genfit wins BTD status at FDA for its lead drug for liver disease; Idorsia outlines $530M '19 spending plans on late-stage R&D

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Gen­fit wins BTD sta­tus at FDA for its lead drug for liv­er dis­ease; Idor­sia out­lines $530M '19 spend­ing plans on late-stage R&D

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Genfit wins BTD status at FDA for its lead drug for liver disease; Idorsia outlines $530M '19 spending plans on late-stage R&D

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC